Top

Published in:

Open Access 01-08-2014 | Research Article

Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer

Authors: József Dudás, Volker H. Schartinger, Angela Romani, Gabriele Schweigl, Kristian Kordsmeyer, Patricia Irina Marta, Christoph Url, Florian Kral, Herbert Riechelmann

Published in: Tumor Biology | Issue 8/2014

Abstract

Excision repair cross complementation group 1 (ERCC1) is a key component of homologous recombination-based repair of interstrand DNA cross-links (ICLs). As a consequence, ERCC1 mediates resistance to mitomycin C (MMC) and platinum chemotherapeutic agents and may predict treatment failure. Clinical response to MMC or cisplatin (CDDP)-based radiochemotherapy (RCT) was assessed in 106 head and neck squamous cell carcinoma (HNSCC) patients and correlated with cell nuclear immunoreactivity of the mouse monoclonal (clone: 8 F1) ERCC1 antibody in tumor tissue samples. BEAS-2B epithelial and Detroit 562 pharyngeal squamous carcinoma cells were treated with CDDP, MMC, and 5-fluorouracil (5-FU) at 50 % growth inhibitory (IC-50) concentrations. ERCC1 protein synthesis was compared with cell cycle distribution using combined immunocytochemistry and flow cytometry. ERCC1 messenger RNA (mRNA) and protein expression was investigated in normoxic and hypoxic conditions in Detroit 562 cells. Clinically, the nonresponder revealed significantly lower HNSCC tissue ERCC1 immunoreactivity than the responder (p = 0.0064) or control normal mucosa, which led to further mechanistic investigations. In vitro, control cells and cells treated with cytotoxic agents showed increasing ERCC1 levels from the G1 through S and G2 phases of the cell cycle. In CDDP-treated cells, ERCC1 mRNA and protein expression increased. Under hypoxic conditions, ERCC1 gene expression significantly decreased. Although ERCC1⁺ cells show increased chemoresistance, they might be particularly radiosensitive, representing G2 cell cycle phase and less hypoxic. ERCC1 expression might be indirectly related with some conditions important for RCT treatment, but it is not a clear predictor for its failure in HNSCC patients.

Available only for authorised users

Bessho T, Sancar A, Thompson LH, Thelen MP. Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J Biol Chem. 1997;272:3833–7.PubMedCrossRef

Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis. 2006;27:997–1007.PubMedCrossRef

Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol. 2004;24:5776–87.PubMedCentralPubMedCrossRef

Núñez F, Chipchase MD, Clarke AR, Melton DW. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21. FASEB J. 2000;14:1073–82.PubMed

Rageul J, Fremin C, Ezan F, Baffet G, Langouet S. The knock-down of ERCC1 but not of XPF causes multinucleation. DNA Repair. 2011;10:978–90.PubMedCrossRef

Yang M, Kim WH, Choi Y, Lee SH, Kim KR, Lee HS, et al. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur J Cancer Prev. 2006;15:269–73.PubMedCrossRef

Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002;94:393–7.PubMedCrossRef

Charuruks N, Shin DM, Voravud N, Ro JY, Hong WK, Hittelman WN. Genetic instability and the development of recurrence of primary tumor and second primary tumor during head and neck tumorigenesis. J Med Assoc Thail. 1996;79(Suppl):S49–55.

Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99:167–72.PubMedCentralPubMedCrossRef

10.

Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:3855–9.PubMedCrossRef

11.

Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med. 2011;9:31.PubMedCentralPubMedCrossRef

12.

Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2009;20:1414–9.PubMedCrossRef

13.

De J, Castro G, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep. 2011;25:693–9.

14.

Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978–83.PubMedCrossRef

15.

Bisof V, Jakovcevic A, Seiwerth S, Rakusic Z, Gasparov S. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. J Cancer Res Clin Oncol. 2013;139:187–94.PubMedCrossRef

16.

Johung K, Rewari A, Wu H, Judson B, Contessa JN, Haffty BG, et al. Role of excision repair cross-complementation 1 expression as a prognostic marker for response to radiotherapy in early-stage laryngeal cancer. Head Neck. 2013;35:852–7.PubMedCrossRef

17.

Forastiere AA. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008;97:701–7.PubMedCrossRef

18.

Hehr T, Classen J, Welz S, Ganswindt U, Scheithauer H, Koitschev A, et al. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. Radiother Oncol. 2006;80:33–8.PubMedCrossRef

19.

Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.PubMedCentralPubMedCrossRef

20.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.PubMedCrossRef

21.

Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol. 2007;85:156–70.PubMedCrossRef

22.

Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, et al. Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol. 2012;126:1–10.CrossRef

23.

Niedernhofer LJ, Bhagwat N, Wood RD. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007;356:2538–40.PubMedCrossRef

24.

Bhagwat N, Olsen AL, Wang AT, Hanada K, Stuckert P, Kanaar R, et al. XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol. 2009;29:6427–37.PubMedCentralPubMedCrossRef

25.

Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res. 2009;69:6831–8.PubMedCentralPubMedCrossRef

26.

Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, et al. XPF Expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011;17:5513–22.PubMedCentralPubMedCrossRef

27.

Riechelmann H, Deutschle T, Grabow A, Heinzow B, Butte W, Reiter R. Differential response of Mono Mac 6, BEAS-2B, and Jurkat cells to indoor dust. Environ Health Perspect. p. 1325–32.

28.

Dudas J, Idler C, Sprinzl G, Bernkop-Schnuerch A, Riechelmann H. Identification of HN-1-peptide target in head and neck squamous cell carcinoma cells. ISRN.Oncol. 2011; 140316.

29.

Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004;24:8504–18.PubMedCentralPubMedCrossRef

30.

Dudas J, Ramadori G, Knittel T, Neubauer K, Raddatz D, Egedy K, et al. Effect of heparin and liver heparan sulphate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulphate. Biochem J. 2000;350(Pt1):245–51.PubMedCentralPubMedCrossRef

31.

Dudas J, Fullar A, Bitsche M, Schartinger V, Kovalszky I, Sprinzl GM, et al. Tumor-produced, active interleukin-1beta regulates gene expression in carcinoma-associated fibroblasts. Exp Cell Res. 2011;317:2222–9.PubMedCentralPubMedCrossRef

32.

Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, et al. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology. 2008;13:510–7.PubMedCrossRef

33.

Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res. 1981;41:1096–9.PubMed

34.

Yasumatsu R, Nakashima T, Uryu H, Masuda M, Hirakawa N, Shiratsuchi H, et al. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells. Oral Oncol. 2009;45:141–7.PubMedCrossRef

35.

Schartinger VH, Galvan O, Riechelmann H, Dudás J. Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy. Support Care Cancer. 2012;20:523–9.PubMedCrossRef

36.

Schmid I, Uittenbogaart CH, Giorgi JV. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry. 1991;12:279–85.PubMedCrossRef

37.

Dudas J, Mansuroglu T, Batusic D, Ramadori G. Thy-1 is expressed in myofibroblasts but not found in hepatic stellate cells following liver injury. Histochem Cell Biol. 2009;131:115–27.PubMedCrossRef

38.

Dudás J, Bitsche M, Schartinger V, Falkeis C, Sprinzl GM, Riechelmann H. Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells. Oral Oncol. 2011;47:98–103.PubMedCentralPubMedCrossRef

39.

Dudas J, Mansuroglu T, Moriconi F, Haller F, Wilting J, Lorf T, et al. Altered regulation of Prox1-gene-expression in liver tumors. BMC Cancer. 2008;8:92.PubMedCentralPubMedCrossRef

40.

Fullár A, Kovalszky I, Bitsche M, Romani A, Schartinger VH, Sprinzl GM, et al. Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma. Exp Cell Res. 2012;318:1517–27.PubMedCentralPubMedCrossRef

41.

Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol. 2001;48:398–406.PubMedCrossRef

42.

Haller F, Kulle B, Schwager S, Gunawan B, on HA, Sultmann H, et al. Equivalence test in quantitative reverse transcription polymerase chain reaction: confirmation of reference genes suitable for normalization. Anal Biochem. 2004;335:1–9.PubMedCrossRef

43.

Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer. 2013;109:2096–105.PubMedCrossRef

44.

Peterson Jr WD, Stulberg CS, Simpson WF. A permanent heteroploid human cell line with type B glucose-6-phosphate dehydrogenase. Proc Soc Exp Biol Med. 1971;136:1187–91.PubMedCrossRef

45.

Wood J, Pring M, Eveson JW, Price N, Proby CM, Hague A. Co-overexpression of Bag-1 and heat shock protein 70 in human epidermal squamous cell carcinoma: Bag-1-mediated resistance to 5-fluorouracil-induced apoptosis. Br J Cancer. 2011;104:1459–71.PubMedCentralPubMedCrossRef

46.

Marples B, Wouters BG, Joiner MC. An association between the radiation-induced arrest of G2-phase cells and low-dose hyper-radiosensitivity: a plausible underlying mechanism? Radiat Res. 2003;160:38–45.PubMedCrossRef

47.

Doan LL, Tanner MK, Grimes HL. Intranuclear staining of proteins in heterogeneous cell populations and verification of nuclear localization by flow cytometric analysis. J Immunol Methods. 2003;279:193–8.PubMedCrossRef

48.

Nias AH. Radiation and platinum drug interaction. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;48:297–314.PubMedCrossRef

49.

Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys. 2006;64:562–72.PubMedCrossRef

50.

Martens-de Kemp SR, Dalm SU, Wijnolts FM, Brink A, Honeywell RJ, Peters GJ, et al. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One. 2013;8:e61555.PubMedCentralPubMedCrossRef

51.

Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10:341–50.PubMedCrossRef

52.

Patel MR, Zhao N, Ang MK, Stadler ME, Fritchie K, Weissler MC, et al. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;149:587–95.PubMedCrossRef

Title: Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer
Authors: József Dudás
Volker H. Schartinger
Angela Romani
Gabriele Schweigl
Kristian Kordsmeyer
Patricia Irina Marta
Christoph Url
Florian Kral
Herbert Riechelmann
Publication date: 01-08-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2001-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Association of promoter methylation of ERα and ERβ with sporadic breast cancer—a study from North India

Ki-67, TGF-β1, and elastin content are significantly altered in lip carcinogenesis

Generation of a monoclonal antibody specific to a new candidate tumor suppressor, cell adhesion molecule 2

Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy

Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion

Modified visor approach applied to total or subtotal glossectomy and reconstruction: avoidance of lip splitting and mandibulotomy and cutting off mental nerve

Keynote webinar | Spotlight on antibody–drug conjugates in cancer